Aspirin, Heparin and Miscarriage
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01917799 |
Recruitment Status
: Unknown
Verified August 2013 by Ishag Adam, University of Khartoum.
Recruitment status was: Recruiting
First Posted
: August 7, 2013
Last Update Posted
: August 7, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pregnancy Miscarriage | Drug: Aspirin Drug: Heparin | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage |
Study Start Date : | January 2009 |
Estimated Primary Completion Date : | November 2013 |
Estimated Study Completion Date : | December 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Aspirin
75mg tab of aspirin once daily
|
Drug: Aspirin
75mg tab of LDA once daily for 7 months
Other Name: LDA
|
Active Comparator: Aspirin + heparin
75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
|
Drug: Aspirin
75mg tab of LDA once daily for 7 months
Other Name: LDA
Drug: Heparin
0.4 mL/day of the Enoxaparin
Other Name: Enoxaparin
|
- Number of miscarriages [ Time Frame: 3 months ]To compare number of miscarriages between the two groups

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 48 Years (Child, Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pregnant women
- History of 2 or more of miscarriage
Exclusion Criteria:
- Twins

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01917799
Libyan Arab Jamahiriya | |
Misurata Teaching Hospital | Recruiting |
Misurata, Libyan Arab Jamahiriya, 218 | |
Contact: Mohamed O Elmahashi, MD +249911259199 essadifathi@hotmail.com | |
Contact: Bashir M Ashur, MD +249911259199 bmashur@yahoo.com |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Ishag Adam, Professor, University of Khartoum |
ClinicalTrials.gov Identifier: | NCT01917799 History of Changes |
Other Study ID Numbers: |
LDA and LMWH |
First Posted: | August 7, 2013 Key Record Dates |
Last Update Posted: | August 7, 2013 |
Last Verified: | August 2013 |
Keywords provided by Ishag Adam, University of Khartoum:
Aspirin Heparin pregnancy miscarriage |
Additional relevant MeSH terms:
Abortion, Spontaneous Pregnancy Complications Aspirin Heparin Calcium heparin Heparin, Low-Molecular-Weight Dalteparin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Anticoagulants |